Cite
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
MLA
Ashida, K., et al. “Randomised Clinical Trial: A Dose-Ranging Study of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Lansoprazole for the Treatment of Erosive Oesophagitis.” Alimentary Pharmacology & Therapeutics, vol. 42, no. 6, Sept. 2015, pp. 685–95. EBSCOhost, https://doi.org/10.1111/apt.13331.
APA
Ashida, K., Sakurai, Y., Nishimura, A., Kudou, K., Hiramatsu, N., Umegaki, E., Iwakiri, K., & Chiba, T. (2015). Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Alimentary Pharmacology & Therapeutics, 42(6), 685–695. https://doi.org/10.1111/apt.13331
Chicago
Ashida, K., Y. Sakurai, A. Nishimura, K. Kudou, N. Hiramatsu, E. Umegaki, K. Iwakiri, and T. Chiba. 2015. “Randomised Clinical Trial: A Dose-Ranging Study of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Lansoprazole for the Treatment of Erosive Oesophagitis.” Alimentary Pharmacology & Therapeutics 42 (6): 685–95. doi:10.1111/apt.13331.